CARB-X

📢 CARB-X announces NEW FUNDING ROUND! CARB-X seeks #preventatives (including #vaccines), #diagnostics, and #therapeutics that address antimicrobial-resistant bacterial infections, specifically: • Therapeutics for infections caused by gram-negative pathogens • Prevention of invasive disease • Diagnostics for neonatal sepsis • Proof-of-concept for novel sample types for diagnosing lower-respiratory-tract infections Applications for all themes must be submitted prior to: Mar. 29, 2024 at 23:59 ET Oct. 4, 2024 at 23:50 ET Details: https://bit.ly/48Sld5D Two public webinars will be held on March 21, 2024 at 19:00 ET and March 22, 2024 at 08:00 ET to discuss the scope of the funding rounds and application process, and to engage in questions and answers with CARB-X staff. The same content will be provided at both. Register at https://bit.ly/3P56UDB #AMR #Superbugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #LMICs Boston University Boston University School of Law Biomedical Advanced Research and Development Authority (BARDA) National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust UK Health Security Agency Department of Health and Social Care Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Novo Nordisk Foundation Government of Canada

Extremely pleased to have delivered the keynote speech at the CARB-X Product Developer conference in Porto last September highlighting the challenges faced by HCPs, parents, and patients in accessing life-saving interventions and diagnostics. Even more pleased with the efforts by CARB-X at addressing these challenges in collaboration with partners, developers, and funders

I had the chance to speak at the CARB-X product developer meeting about the ways in which the program has added value beyond the funding. Preparing for the talk gave me an opportunity to reflect on how much being a part of CARB-X has shaped our program management and expertise development as an organization. It forced us to add rigor to our milestones, document our methods and performance at each stage of development, and expanded our access to expertise that we sorely needed. We started off with some strong skills but a lot of naivety about so many topics, like the web of competing regulations on AST testing. Our CARB-X advisors Betsy Wonderly Trainor Peter J. Dailey Tom Lowery Linda Miller Richard Alm and the Biomedical Advanced Research and Development Authority (BARDA) representatives who follow our program challenged us with their questions, initial skepticism, and clinical/market experience. Today, I consider our team to be world class experts in all of the critical domains we touch because we were pushed to become so by CARB-X. It’s been an honor to be one of their #diagnostic portfolio companies. Thanks to Kevin Outterson Erin Duffy for their leadership. Boston University School of Law National Institute of Allergy and Infectious Diseases (NIAID) Bill & Melinda Gates Foundation Wellcome Trust Bundesministerium für Bildung und Forschung UK Health Security Agency Novo Nordisk Foundation Government of Canada

⏰ REMINDER: Expressions of Interest are due tomorrow! Expressions of Interest must be submitted to the CARB-X Portal by tomorrow, Oct. 4 at 23:59 ET, to be considered for the 2024 CARB-X funding round for new #preventatives, #diagnostics, and #therapeutics to address drug-resistant bacteria. 🔗 Apply here: bit.ly/3P56UDB #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology #Antibiotics

EU-JAMRAI 2 welcomes the commitment made by the countries attending the #UNGA High Level Meeting on Antimicrobial Resistance, where world leaders came together to adopt a political declaration aimed at reducing #AMR. Key 2030 targets include: ✔️ Reducing bacterial resistance-related deaths by 10%. ✔️ Developing and implementing national action plans on AMR in all countries. ✔️ Securing $100 million to support at least 60% of countries in completing funded national plans. The Antimicrobial Resistance Symbol was worn by many high-level attendees, standing out as a symbol that unites us all. Its design – two hearts sliding together to form two pills – underscores the need for care and urgent action to fix this issue. As stated by EU Commissioner Stella Kyriakides, we must strengthen global coordination and allocate resources to address AMR as a top health priority. Together, let’s build a One Health world to reduce AMR. 💊❤️ More info: https://lnkd.in/dQmPkykN #AMR #OneHealth #GlobalHealth #EUJAMRAI #UNGA #HealthInnovation #Collaboration

Thank you to CARB-X product developers, funders, and speakers who convened in Porto, Portugal, on September 16 for the annual CARB-X PD Conference!  More than 100 participants gathered to learn about clinical challenges while working in resource-limited settings, patients’ perspectives, innovation in antibacterial R&D, low- and middle-income country market needs, and more. CARB-X also hosted breakout sessions on #therapeutics, #preventatives, and #diagnostics, giving product developers opportunities to connect with experts in their field.   A special thank you to our speakers Erin Duffy, Usman Nakakana, Leticia de Oliveira Batista, Vanessa Carter, Pernilla Rönnholm, Kevin Outterson, Jong Lee, Alice Troy, Michael Kowarik, Herb Harwell, Trudy Grossman, and Damiano de Felice.    CARB-X remains committed to addressing drug-resistance by hosting events where product developers in the CARB-X Portfolio can connect and share their innovative research and development with stakeholders and the CARB-X team. #AntimicrobialResistance #AMR #SuperBugs #StopSuperBugs #GlobalHealth #Medicine  Boston University Boston University School of Law Biomedical Advanced Research and Development Authority (BARDA) The National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust UK Health Security Agency Department of Health and Social Care Bundesministerium für Bildung und Forschung Bill & Melinda Gates Foundation Novo Nordisk Foundation Government of Canada

CARB-X welcomes the approval of the Political Declaration on antimicrobial resistance (AMR) by United Nations Member States during the High-Level meeting that took place yesterday at the 79th Session of the UN General Assembly. UN Member States recognized “the benefits of public-private partnerships in the development of and access to antimicrobials, vaccines, diagnostics and alternatives to antimicrobials and in contributing to supply chain sustainability and take note of the work of the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) and the Global Antibiotic Research and Development Partnership (GARDP).” “While bacterial infections already kill millions of people annually and antimicrobial resistance is on the rise, the clinical pipeline of antibacterial products is insufficient, requiring innovative solutions that include a unified, global effort to invest in research and development,” said Damiano de Felice, Chief of External Affairs at CARB-X. “We are grateful for the United Nations’ recognition and commitment to the advancement of antibacterial innovation, access and stewardship, especially the work done by public-private partnerships such as CARB-X and GARDP. We remain committed to supporting the most promising R&D projects for infections whose burden is most heavily felt in low- and middle-income countries, and to attaching clear conditions facilitating global access and stewardship to our grants.” 🔗 Read our press release here: bit.ly/3Bh0Eoi #AMR #StopSuperBugs #AntimicrobialResistance #UNGA #Medicine #GlobalHealth

Live from the United Nations High-Level Meeting on Anti-Microbial Resistance, discussing the adoption of the Political Declaration. CARB-X is here to provide solutions to this multi-faceted problem.

Tackling antimicrobial resistance (AMR) requires international collaboration to preserve the effectiveness of existing treatments and develop new, affordable, and accessible solutions. Last night in New York, the Novo Nordisk Foundation and Healthcare Denmark hosted a High-Level Reception with Denmark In New York, bringing together key global stakeholders. The event allowed experts to share insights on the impact of #AMR and strategies to combat it, ahead of today's United Nations General Assembly High-Level Meeting on Antimicrobial Resistance.

CARB-X is pleased to support EU-JAMRAI's initiative in promoting antimicrobial resistance awareness with these pins, a global symbol of AMR. The symbol is formed by three objects: medicine capsules, setting the theme of antibiotics; a heart, telling us we need to care about AMR; and two bandages, telling us we need to fix the problem. We encourage those in New York for the United Nations High-Level Meeting on AMR to wear these pins with pride to send a unified message: “The time to address AMR is now.” 🔗 Learn more: bit.ly/4edZvw1